BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
11.04
-0.15 (-1.34%)
At close: Jun 4, 2025, 4:00 PM
11.20
+0.16 (1.45%)
After-hours: Jun 4, 2025, 7:49 PM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 580 employees as of December 31, 2024. The number of employees increased by 44 or 8.21% compared to the previous year.
Employees
580
Change (1Y)
44
Growth (1Y)
8.21%
Revenue / Employee
$868,078
Profits / Employee
-$92,190
Market Cap
2.31B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BCRX News
- 1 day ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewsWire
- 5 days ago - BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages - GlobeNewsWire
- 8 days ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewsWire
- 21 days ago - BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years - GlobeNewsWire
- 4 weeks ago - BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors - Benzinga
- 4 weeks ago - BioCryst: Strong Opportunity For A Double With A Proven Therapy - Seeking Alpha